Kris Jenner has described peptide injections as a 'game changer' after saying that Ozempic made her so nauseous she could no longer work. The 70-year-old businesswoman made the remarks on the SHE MD Podcast on Tuesday 5 May 2026. Her comments come as US regulators reconsider how certain peptides may be used in compounded medicines.

What Jenner Said About Ozempic and Peptides

Jenner told hosts Dr Thais Aliabadi, an obstetrician-gynaecologist, and women's advocate Mary Alice Haney that she tried Ozempic once and it made her 'really sick'. She said she told Aliabadi, who is also her doctor, that the nausea meant she could no longer work.

Aliabadi suggested trying something else. After the pair considered several options, Jenner settled on a peptide injection, followed by supplements. She said her doctor recommends fish oil and omega-3s. Jenner also said the routine gave her a couple of extra hours of energy in the evening, and helped her hair, skin and nails.

Key facts: Jenner, 70, appeared on the SHE MD Podcast on 5 May 2026. She said Ozempic made her too nauseous to work. She now uses peptide injections plus supplements. Peptides marketed for wellness are largely unapproved, and US regulators have not yet added any of those under review to the compounding list.

Why Doctors and Regulators Urge Caution on Peptides

Peptides are short chains of amino acids that perform various functions in the body. Some, including semaglutide, the active ingredient in Ozempic, are used in established medical treatments and have undergone extensive clinical research. Others marketed for wellness, recovery or anti-ageing have limited human evidence, and their safety, effectiveness and quality may be uncertain.

Health professionals advise taking any peptide treatment only under medical supervision.

ECRI and the Institute for Safe Medication Practices (ISMP) have warned that the compounded peptide market has outpaced the evidence on safety and effectiveness. A study of falsified peptide products obtained from suspected illegal online pharmacies found purity levels ranging from 5% to 75% in certain samples. It also identified arsenic and lead contamination, with some samples exceeding toxicity limits for injectable drugs.

The American Medical Association has noted that the effects of some peptides have not been studied extensively, with possible side effects ranging from stomach discomfort to pancreatitis.

Read more

Kris Jenner Peptide Injections Meet a Shifting FDA Position

The regulatory picture has moved quickly this year. In April 2026, a federal policy change altered the regulatory classification of 12 peptides used in compounding. ECRI and the Institute for Safe Medication Practices warned that the change did not reflect new evidence establishing the products' safety or effectiveness.

On 29 June, FDA staff recommended against adding seven peptides under review to the list of bulk drug substances that may be used in compounding. At a meeting on 23 and 24 July, the agency's advisory committee recommended adding six of the seven, with several votes passing by narrow margins, including 8–6.

The recommendations are non-binding and do not, by themselves, authorise compounding with those substances. The committee has also faced scrutiny over potential conflicts of interest among members. On 24 August, the FDA issued five warning letters to online peptide vendors.

On 14 October 2026, the FDA and the Department of Health and Human Services submitted an Interim Access Policy for Compounding Using Certain Peptides for review by the Office of Management and Budget. As of 28 October, the policy remained under review, and the July committee recommendations had not themselves added the six peptides to the Section 503A Bulks List.

The policy's eventual effect on access to compounded peptides remains uncertain while the proposal is under review. Jenner has described her own experience with peptide injections, but her account does not establish their safety or effectiveness for other people.

Read more